Episode 20: The Role of Complement in Kidney Diseases

Matthew Pickering, MD (Imperial College London, United Kingdom), discusses the distinction between complement-driven and complement-associated kidney diseases. The conversation highlights the clinical implications of this difference, new therapies such as C3 and C5 inhibitors, and the role of biomarkers in advancing precision medicine.

Episode 21: Diagnosis and Management of C3G

David Kavanagh, MD (National Renal Complement Therapeutics Centre, United Kingdom), shares insights into how patients present with C3 Glomerulopathy, the steps needed to confirm a diagnosis, and the limitations of traditional immunosuppression. He also explores the potential of alternative pathway inhibitors and the unique challenges of post-transplant recurrence.

Episode 22: Advancing Research and Novel Therapies for C3G

Nicole van de Kar, MD (Radboud University Medical Center, The Netherlands) discusses the underlying pathophysiology of C3G, including genetic and autoantibody factors. She examines why the alternative pathway plays such a central role, the limits of current C5 therapies, and how new approaches targeting C3 activation may reshape treatment in the future.

Episode 23: A Patient and Caregiver Perspective

Marianne Silkjaer Nielsen (Founder of CompCure, Denmark) offers a powerful voice for patients and caregivers. She reflects on the long diagnostic journey, the challenges of managing rare kidney disease, and the need for better awareness, advocacy, and international registries to improve outcomes.

This series was supported by Apellis and Sobi.